Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-12
2011-07-12
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000
Reexamination Certificate
active
07977337
ABSTRACT:
Disclosed are quinoline compounds having affinity for the 5-HT6receptor and having the formula:where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
REFERENCES:
patent: 5576338 (1996-11-01), Friesen et al.
patent: 5596001 (1997-01-01), Hamanaka
patent: 6172084 (2001-01-01), Cuny et al.
patent: 6187805 (2001-02-01), Pineiro et al.
patent: 6207679 (2001-03-01), Cuny et al.
patent: 6310212 (2001-10-01), Yuan et al.
patent: 6316450 (2001-11-01), Bromidge et al.
patent: 6376670 (2002-04-01), Cuny et al.
patent: 6380199 (2002-04-01), Reavill et al.
patent: 6403808 (2002-06-01), Glennon et al.
patent: 6489488 (2002-12-01), Glennon et al.
patent: 6518297 (2003-02-01), Glennon et al.
patent: 6548504 (2003-04-01), Bromidge et al.
patent: 6787535 (2004-09-01), Beard et al.
patent: 6849644 (2005-02-01), Bromidge et al.
patent: 7084169 (2006-08-01), Zhao
patent: 7087750 (2006-08-01), Caldirola et al.
patent: 7098233 (2006-08-01), Di Cesare et al.
patent: 7262188 (2007-08-01), MacDonald et al.
patent: 7452888 (2008-11-01), Ahmed et al.
patent: 7601837 (2009-10-01), Ahmed et al.
patent: 2001/0051719 (2001-12-01), Bromidge et al.
patent: 2003/0144505 (2003-07-01), Bromidge et al.
patent: 2004/0024210 (2004-02-01), Johansson et al.
patent: 2004/0034036 (2004-02-01), Bromidge et al.
patent: 2004/0132742 (2004-07-01), Bromidge et al.
patent: 2004/0167030 (2004-08-01), Berontas et al.
patent: 2005/0090485 (2005-04-01), Bromidge et al.
patent: 2005/0090496 (2005-04-01), Ahmed et al.
patent: 2005/0176705 (2005-08-01), Bromidge
patent: 2005/0176759 (2005-08-01), Ahmed et al.
patent: 2006/0287334 (2006-12-01), Johnson et al.
patent: 2007/0027139 (2007-02-01), Johnson et al.
patent: 2007/0032504 (2007-02-01), Gladwin
patent: 2007/0191345 (2007-08-01), Ahmed et al.
patent: 2007/0249603 (2007-10-01), Johnson et al.
patent: 2007/0275979 (2007-11-01), Macdonald et al.
patent: 2169231 (1996-08-01), None
patent: 0 605 981 (1996-02-01), None
patent: 0 818 449 (1998-01-01), None
patent: 0 631 176 (2000-12-01), None
patent: 0 867 477 (2002-05-01), None
patent: 2341549 (2000-03-01), None
patent: 02262627 (1990-10-01), None
patent: WO 95/11592 (1995-05-01), None
patent: WO 97/32858 (1997-09-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/47874 (1998-10-01), None
patent: WO 98/54157 (1998-12-01), None
patent: WO 98/54158 (1998-12-01), None
patent: WO 98/57931 (1998-12-01), None
patent: WO 98/57952 (1998-12-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 99/47516 (1999-09-01), None
patent: WO 99/65906 (1999-12-01), None
patent: WO 99/65906 (1999-12-01), None
patent: WO 00/12073 (2000-03-01), None
patent: WO 00/13681 (2000-03-01), None
patent: WO 00/34265 (2000-06-01), None
patent: WO 00/42026 (2000-07-01), None
patent: WO 00/58303 (2000-10-01), None
patent: WO 00/58313 (2000-10-01), None
patent: WO 00/63203 (2000-10-01), None
patent: WO 00/63203 (2000-10-01), None
patent: WO 00/64877 (2000-11-01), None
patent: WO 01/16108 (2001-03-01), None
patent: WO0117963 (2001-03-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 01/32660 (2001-05-01), None
patent: WO 01/40217 (2001-06-01), None
patent: WO0198279 (2001-12-01), None
patent: WO 02/08178 (2002-01-01), None
patent: WO 02/20489 (2002-03-01), None
patent: WO 02/28837 (2002-04-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/44170 (2002-06-01), None
patent: WO 02/089811 (2002-11-01), None
patent: WO 02/098857 (2002-12-01), None
patent: WO 02/102774 (2002-12-01), None
patent: WO 03/011284 (2003-02-01), None
patent: WO 03/013510 (2003-02-01), None
patent: WO03014097 (2003-02-01), None
patent: WO 03020707 (2003-03-01), None
patent: WO 03/037872 (2003-05-01), None
patent: WO 03/066056 (2003-08-01), None
patent: WO 03/072558 (2003-09-01), None
patent: WO 03/080608 (2003-10-01), None
patent: WO03095434 (2003-11-01), None
patent: WO 2004/000828 (2003-12-01), None
patent: WO03104193 (2003-12-01), None
patent: WO2004026830 (2004-04-01), None
patent: WO2004026831 (2004-04-01), None
patent: WO2004035047 (2004-04-01), None
patent: WO2004041792 (2004-05-01), None
patent: WO 2004050085 (2004-06-01), None
patent: WO2004078176 (2004-09-01), None
patent: WO2004080969 (2004-09-01), None
patent: WO 2005/021530 (2005-03-01), None
patent: WO 2006/038006 (2006-04-01), None
patent: WO 2007/039219 (2007-04-01), None
patent: WO 2007/039220 (2007-04-01), None
patent: WO 2007/039238 (2007-04-01), None
Mitchell et al.,Pharmacol.&Therapeutics, 108: 320-333 (2005).
Chuang et al.,Alzheimer's&Dementia, The Journal of the Alzheimer's Association, 2(3/Supp. 1):S631-S632 (2006).
London Stock Exchange Announcement—GlaxoSmithKline (GSK) plc, Issued on Thursday, Dec. 13, 2007, New York, New York.
A Dose Ranging Study to Investigate the Efficacy and Safety of SB-742457 in Alzheimer's Disease. NCT ID No. NCT00224497 (Verified 2007).
SB-742457 and Donepezil in Alzheimer's Disease. NCT ID No. NCT00348192 (2006).
Garcia-Alloza et al.Neuropsychopharmacology, 29: 410-416 (2004).
Davies et al.,Drugs of the Future, 30(5): 479-495 (2005).
Boes et al.Eur. J. Med. Chem., 36(2): 165-178 (2001).
Hirst et al.Mol. Pharmacol., 64: 1295-1308 (2003).
Sleight et al.Br. J. Pharmacol., 124(3): 556-562 (1998).
Lindner et al.J. Pharmacol. Exp. Ther., 307(2): 682-691 (2003).
Riemer et al.J. Med. Chem., 46(7): 1273-1276 (2003).
Chang-Fong et al.Bioorg. Med. Chem. Lett., 14(8): 1961-1964 (2004).
Glennon et al.J. Med. Chem., 43(5): 1011-1018 (2000).
Russell et al.,J. Med.Chem., 44(23): 3881-3895 (2001).
Pineiro-Nunez et al.229thACS Natl. Mtg., Mar. 13-17, San Diego, Abst. Medi 282 (2005).
Stadler et al.37thIUPAC Cong. Aug. 14-19, Berlin, Abst MM-7 (1999).
Holenz et al.J. Med. Chem., 48(6): 1781-1795 (2005).
Ahmed et al.Bioorganic&Medicinal Chem. Letters., 15: 4867-4871 (2005).
Bourson et al.British Journal of Pharmacol., 125: 1562-1566 (1998).
Sleight et al.British Journal of Pharmacol., 124: 556-562 (1998).
Bentley et al.British Journal of Pharmacol., 126: 1537-1542 (1999).
Bentley et al.British Journal of Pharmacol., 126 (Suppl.): 66 (1999).
Thome et al.Journal of Neural Transmission, 108: 1175-1180 (2001).
Bentley et al.Journal of Psychopharmacology, A64 (Suppl.): 255 (1997).
Foley et al.Neuropsychopharmacology, 29: 93-100 (2004).
Tsai et al.Neuroscience Letters, 276: 138-139 (1999).
Kan et al.Neuroscience Letters, 372: 27-29 (2004).
Bourson et al.J. Pharmaco. &Exp. Therapeutics, 274: 173-180 (1995).
Robichaud et al.Annual Reports in Med. Chem., 36: 11-20 (2000).
Rogers et al.Psychopharmacology, 158: 114-119 (2001).
Bromidge et al.Bioorg. &Med. Chem. Lett., 11: 55-58 (2001).
Wesolowska, et al. “Effects of the Brain-Penetrant and Selective 5-HT6 Receptor Antagonist SB-399885 in Animal Models of Anxiety and Depression”.Neuropharmacology, 52: 1274-1283 (2007).
Glennon, et al. “2-Substituted Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors”.J. Med. Chem., 43: 1011-1018 (2000).
Ahmed Mahmood
Johnson Christopher Norbert
Jones Martin C
MacDonald Gregor James
Moss Stephen Frederick
Bernhardt Emily
Glaxo Group Limited
Lemanowicz John
Sieburth Kathryn L.
LandOfFree
Quinoline derivatives and their use as 5-HT6 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline derivatives and their use as 5-HT6 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives and their use as 5-HT6 ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731106